Summary
Sarepta Therapeutics' shares fell sharply in premarket trading on Thursday after the company disclosed a pronounced year-over-year decline in Elevidys sales for the first quarter. Management attributed the fall in product revenue to a narrower patient population eligible for treatment under an updated label issued by the Food and Drug Administration. While total revenue decreased slightly, collaboration revenues helped to partially offset the downturn in product sales.
Details of the quarter
The company reported that Elevidys generated $102 million in first-quarter revenue, compared with $375 million in the same quarter of 2025. Sarepta said this reduction reflects lower sales volume following an updated label that restricts Elevidys treatment to ambulatory patients. The FDA implemented the label change last year after safety concerns and patient deaths prompted regulatory review and a temporary halt in shipments.
Total reported revenue for the quarter was $730.8 million, down $14.1 million from the prior year period. Sarepta noted that the overall decline in revenue was partially offset by higher collaboration revenues.
On the market, the stock slid 10.3% to $122.96 in premarket trading on Thursday. Despite the recent drop, the shares had registered a 7% gain year to date through Wednesday's close.
Key implications and context
- Product revenue for Elevidys fell materially year over year, driven by a reduced eligible patient pool under the updated FDA label.
- Total company revenue edged down modestly, with collaboration income cushioning some of the impact from lower product sales.
- Market reaction was swift, with shares declining in premarket trading following the disclosure.
Observed risks and uncertainties
- Regulatory constraints - The updated FDA label limiting Elevidys to ambulatory patients has directly reduced sales volume and therefore product revenue.
- Safety-related scrutiny - Prior safety concerns and patient deaths prompted both regulatory review and a temporary shipment halt, creating ongoing uncertainty around commercial uptake.
- Revenue pressure and market sensitivity - Declining product sales have already weighed on the stock price, illustrating sensitivity in the capital markets to changes in therapy eligibility and uptake.
These points reflect the information the company disclosed regarding sales trends, regulatory actions, and the immediate market reaction.